CD19 and B-cell non-Hodgkin lymphoma: EMA- and FDA-approved CD19-CAR T cells and BsAbs for the treatment of B-cell lymphomas are improving patients’ survival after failure of previous standard-of-care treatment; however, the onset of molecular resistance represents a threat to their clinical efficacy.